Physician profile
Laura E Dressel
NPI 1528001898
$5,417.66
in general payments reported to CMS, 2019-2025
44 companies · $919 in 2025
The $919 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $236 · 2021: $747 · 2022: $867 · 2023: $858 · 2024: $971 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,747 · Education: $1.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,747.20 |
| Education | $1.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $644.22 | 2019-2025 | |
| Novo Nordisk INC | $594.82 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $529.03 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $498.36 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $368.69 | 2019-2025 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals LP | $341.76 | 2019-2025 | Farxiga, Nexium, Airsupra |
| Lilly USA, LLC | $304.56 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Radius Health, INC. | $192.26 | 2019-2025 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.80 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.34 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $154.72 | 2019-2023 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $127.68 | 2019-2023 | Trintellix |
| Corcept Therapeutics | $120.99 | 2023-2025 | Korlym |
| Astellas Pharma US INC | $103.69 | 2020-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $95.57 | 2021-2024 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $86.18 | 2019-2024 | Octrode, Freestyle Libre 3 |
| Exact Sciences Corporation | $73.89 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $67.32 | 2019-2024 | |
| Eisai INC. | $64.38 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $52.52 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $51.46 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $48.77 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $46.53 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $45.71 | 2022 | |
| Averitas Pharma INC. | $45.49 | 2024 | Qutenza |
| Inari Medical, INC. | $43.33 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Avanir Pharmaceuticals, INC. | $42.60 | 2019 | |
| Merck Sharp & Dohme LLC | $40.76 | 2019-2021 | |
| Allergan, INC. | $34.98 | 2019 | |
| Dexcom, INC. | $25.61 | 2024 | Dexcom G6 Transmitter |
| Stryker Corporation | $20.19 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Xeris Pharmaceuticals, INC. | $19.51 | 2023 | Gvoke Hypopen |
| Nevro Corp. | $18.69 | 2023 | Senza |
| Medtronic, INC. | $18.46 | 2025 | Intellis Adaptivestim |
| Preventric Diagnostics, INC. | $17.76 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.66 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.22 | 2022 | |
| Sanofi Pasteur INC. | $16.46 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $16.16 | 2021 | |
| Grt US Holding, INC. | $15.62 | 2021 | |
| Boston Scientific Corporation | $15.25 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $14.61 | 2024 | Evkeeza |
| E.R. Squibb & Sons, L.L.C. | $13.21 | 2019 | |
| Amarin Pharma, INC. | $12.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Dressel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.